Yogesh Reddy
@yreddyhf
HF doc at Mayo Clinic, interested in HFpEF, PAH, valve hemodynamics
Wrapping up Day 2 of the #CharlestonHFpEF Conference, Dr. Yogesh Reddy from Mayo delivered the best breakdown yet of how SGLT2 inhibitors and GLP-1 agonists really work. Clear, sharp, and full of insight—HFpEF minds left buzzing. 💊🫀 #HFpEF @yreddyhf @MayoCVservices
At #CharlestonHFpEF, Dr. Gaggin took the mic, From MGH, her insights strike. TTR amyloid—know what’s true, PYP scans can mislead you. Rule out AL, don’t just assume, MRI rarely clears the room. For diagnosis sharp and sound, Trust the clues when they are found. We’ve got…
Exercise intolerance in HFpEF is almost all about the heart, and little to do with the periphery. Skeletal muscle changes reported are similar to those in multiple other non-HFpEF diseases likely due to heart failure induced sedentariness + deconditioning rdcu.be/ewAxS
Gp 1 PH with high HFpEF probability have less clinical improvement with traditional PH therapy, compared to gp 1 PH + low HFpEF prob. Do we need more intensive PH therapy, sotatercept or HFpEF therapies for these pts? Many unknowns that need RCTs. publications.ersnet.org/content/erj/ea…
ESC Congress Madrid 2025 HOT LINE 2 30 August from 08:15 to 09:45 Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial VICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational…
#ESCCongress2025: Will #vericiguat have a role in chronic heart Failure? VICTOR study will be presented at Hot Line 2 (Did someone read a press release from Bayer? I didn't...). @HanCardiomd @mvaduganathan @hvanspall @SJGreene_md @SantosGallegoMD @luisbeckdasilva
🧠 Tirzepatide doesn’t just reduce appetite—it rewires the brain. - - - A new Nature Medicine Phase 1 RCT (n=114) explored how tirzepatide changes eating behavior—and the brain’s response to food—in people with overweight or obesity. 📉 Key Findings at 3–6 Weeks 🔹-524 kcal/day…
Hemodynamic guided and device free interatrial shunting for HFpEF - a simpler approach? heart.bmj.com/content/early/…
Not all weight loss is good in HFpEF. Unintentional weight loss is different than therapeutic weight loss in HFpEF onlinelibrary.wiley.com/doi/10.1002/ej…
Clinically we use wedge pressure to estimate LA pressure during RHC. In a large transeptal hemodynamic series we show that wedge pressure can be higher than true LAP likely due to pulmonary venous disease and collaterals with implications for PH diagnosis academic.oup.com/eurheartj/adva…
More evidence that not all group 1 PH is the same. In the blue journal we show how clinical gp 1 PH with high HFpEF probability is metabolomically distinct from traditional gp 1 PH, and more similar to clinical HFpEF. atsjournals.org/doi/abs/10.116… @ATSBlueEditor @MayoClinicCV
Pooled analysis of obesity and kidney outcomes from 4 HFpEF RCTs now in @JACCJournals 👥 n=16,919 ⬆️ waist circumference ➡️ higher kidney risk🫘🏥 ⬆️ waist-to-height ratio ➡️ higher kidney risk 🫘🏥 But not for BMI 🤔 sciencedirect.com/science/articl… @mvaduganathan @TorBiering
🔥 #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.10…
Higher HFpEF probability in group 3/4 PH is associated with dynamic PCWP abnormalities, worse functional status and quality of life. @yreddyhf @mayoclinicCV @JaneALeopold @FrantzDrBob @WilsonTangMD @bborlaugmd @ebrosenzweig @SteveMathaiMD @ChrisJellisMD ahajrnls.org/4mJTDiV
Patient with lung disease or sleep apnea often develop precapillary PH considered group 3/4 PH. Here we show that dynamic PCWP abnormalities are very common in these pts. Trials of HFpEF therapies are needed. @CircHF @MayoClinicCV ahajournals.org/eprint/Y3PHYGT…
🔥HOT #HeartFailure2025 PRAISE-HFrEF 📍No suggestion of⬆️ HFH or ☠️ with GLP1-RA use at diabetes doses 📍Probable safety of GLP-1RA in clinically severe HFrEF with obesity 📍Hypothesis generating data 📍Need for RCT at weight loss doses, especially with severe obesity and/or CKD
#VICTORIA demonstrated benefits of sGC stimulator vericiguat in recent worsening HF & led to its #FDA approval in '21 New @JACCJournals nationwide analysis finds use thus far has been limited jacc.org/doi/abs/10.101… Will #VICTOR (no recent worsening HF) support its broader use?
Vericiguat Adherence for Heart Failure With Reduced Ejection Fraction in Routine Clinical Care in the U.S New RL @JACCJournals Heart Failure, led by star med student Naira Ikram @mvaduganathan @ankeetbhatt jacc.org/doi/abs/10.101…
“What’s Old is New Again!” - @CMichaelGibson The MR / aldosterone axis remains in central focus for the *treatment* and now *prevention* of heart and kidney disease in 2025
Dr. Vaduganathan and I discuss the pivotal role of the MRA Axis in the treatment of heart failure and other chronic disease states.